"Dopamine Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
| Descriptor ID |
D015259
|
| MeSH Number(s) |
D27.505.519.625.150 D27.505.696.577.150
|
| Concept/Terms |
Dopamine Agents- Dopamine Agents
- Agents, Dopamine
- Dopaminergic Agents
- Agents, Dopaminergic
- Dopaminergic Drugs
- Drugs, Dopaminergic
- Dopamine Drugs
- Drugs, Dopamine
Dopamine Effect- Dopamine Effect
- Effect, Dopamine
- Dopaminergic Effect
- Effect, Dopaminergic
- Dopaminergic Effects
- Effects, Dopaminergic
- Dopamine Effects
- Effects, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agents".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agents".
This graph shows the total number of publications written about "Dopamine Agents" by people in this website by year, and whether "Dopamine Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 4 | 1 | 5 |
| 2018 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 Jul; 42:102163.
-
A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 03; 1867(3):275-285.
-
Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord. 2018 07; 33(7):1099-1107.
-
Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials. Clin Pharmacol Ther. 2019 01; 105(1):121-130.
-
The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj. 2018; 32(8):1050-1055.
-
Reward sensitivity in Parkinson's patients with binge eating. Parkinsonism Relat Disord. 2018 06; 51:79-84.
-
Relevance of sleep quality on caregiver burden in Parkinson's disease. Neurol Sci. 2018 May; 39(5):835-839.
-
Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. J Am Geriatr Soc. 2018 01; 66(1):170-178.
-
Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. Mov Disord. 2017 Nov; 32(11):1557-1565.
-
Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2017 Jun; 37(3):341-346.